Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K et al
Prescribing GLP-1s: Evidence, limits, expectations How physicians integrate GLP1s into long-term weight management GLP-1 medications are reshaping the conversation around metabolic health and weight loss but questions remain
Acta Neuropsychiatrica
25 Although data from clinical studies on liraglutide revealed a 7% increase in serum amylase and a 31% increase in serum lipase in patients after four weeks of GLP-1 receptor agonist treatment compared with placebo, the increased levels reverted to normal once therapy was discontinued and did not predict acute pancreatitis onset
This pattern reflects the chronic, relapsing nature of obesity and has prompted the WHO to recommend continuous, long-term treatment lasting six months or moreeffectively positioning these medications as lifetime therapies for many patients [51]
Enhances Fat Burning for Energy Production